Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$32.10
+1.7%
$29.38
$23.23
$42.29
$1.04B0.64367,350 shs179,420 shs
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$21.91
+9.9%
$19.60
$13.30
$30.03
$1.07B0.83363,297 shs367,526 shs
2seventy bio, Inc. stock logo
TSVT
2seventy bio
$5.00
$5.00
$2.29
$5.30
$266.15M1.04646,979 shsN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$1.67
+0.1%
$2.99
$1.64
$26.96
$9.76M0.54195,191 shs416,398 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
+2.17%+4.19%+4.54%+19.72%-1.03%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
+1.74%+1.42%-3.91%+20.64%-11.22%
2seventy bio, Inc. stock logo
TSVT
2seventy bio
0.00%0.00%0.00%+1.21%+26.58%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-1.19%-10.48%-61.28%-76.08%-90.45%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
4.1756 of 5 stars
3.41.00.03.03.80.81.9
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
2.6774 of 5 stars
3.50.00.00.03.74.20.0
2seventy bio, Inc. stock logo
TSVT
2seventy bio
N/AN/AN/AN/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
4.6406 of 5 stars
3.52.00.04.60.63.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2.75
Moderate Buy$43.7536.29% Upside
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
3.00
Buy$41.2088.08% Upside
2seventy bio, Inc. stock logo
TSVT
2seventy bio
2.00
Hold$5.00N/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.00
Buy$72.334,241.74% Upside

Current Analyst Ratings Breakdown

Latest TSVT, XFOR, ELVN, and COLL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$40.00 ➝ $48.00
6/16/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$40.00 ➝ $52.00
6/16/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$37.00
5/16/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$36.00 ➝ $27.00
5/15/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$39.00 ➝ $40.00
5/10/2025
2seventy bio, Inc. stock logo
TSVT
2seventy bio
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (D-)
5/9/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.00
5/2/2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1.50 ➝ $7.00
4/24/2025
2seventy bio, Inc. stock logo
TSVT
2seventy bio
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (E+)
4/9/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$631.45M1.63$12.84 per share2.50$7.10 per share4.52
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/A$6.34 per shareN/A
2seventy bio, Inc. stock logo
TSVT
2seventy bio
$48.37M5.50N/AN/A$5.04 per share0.99
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$2.56M3.77N/AN/A$3.90 per share0.43
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$69.19M$1.2226.425.33N/A6.61%99.08%15.14%8/6/2025 (Estimated)
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$89.02M-$1.92N/AN/AN/AN/A-31.84%-30.09%8/12/2025 (Estimated)
2seventy bio, Inc. stock logo
TSVT
2seventy bio
-$217.57M-$0.10N/AN/AN/A-207.25%-53.65%-23.67%8/6/2025 (Estimated)
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$37.45M$2.140.79N/AN/A46.54%-181.56%-54.36%8/6/2025 (Estimated)

Latest TSVT, XFOR, ELVN, and COLL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.88N/AN/AN/A$182.26 millionN/A
8/6/2025Q2 2025
2seventy bio, Inc. stock logo
TSVT
2seventy bio
-$0.05N/AN/AN/A$15.45 millionN/A
5/14/2025Q1 2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$0.51-$0.57-$0.06-$0.57N/AN/A
5/8/2025Q1 2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.50$1.49-$0.01$0.07$174.96 million$177.76 million
5/7/2025Q1 2025
2seventy bio, Inc. stock logo
TSVT
2seventy bio
-$0.10$0.01+$0.11$0.01$13.96 million$22.94 million
5/1/2025Q1 2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$4.13$0.04+$4.17$0.04$7.03 million$28.81 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/AN/AN/AN/AN/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/AN/A
2seventy bio, Inc. stock logo
TSVT
2seventy bio
N/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
3.30
1.08
1.01
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/A
21.07
21.06
2seventy bio, Inc. stock logo
TSVT
2seventy bio
N/A
4.95
4.95
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.30
3.70
3.58

Institutional Ownership

CompanyInstitutional Ownership
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/A
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
95.08%
2seventy bio, Inc. stock logo
TSVT
2seventy bio
93.90%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
72.03%

Insider Ownership

CompanyInsider Ownership
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2.51%
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
25.90%
2seventy bio, Inc. stock logo
TSVT
2seventy bio
7.20%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
2.15%
CompanyEmployeesShares OutstandingFree FloatOptionable
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
21032.13 million31.33 millionOptionable
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
5049.07 million36.36 millionOptionable
2seventy bio, Inc. stock logo
TSVT
2seventy bio
44053.23 million47.87 millionOptionable
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
805.79 million5.67 millionOptionable

Recent News About These Companies

X4 Pharmaceuticals, Inc. (XFOR) - Yahoo Finance
XFOR X4 Pharmaceuticals, Inc. - Seeking Alpha
X4 Pharmaceuticals Analyst Ratings
Earnings Preview For X4 Pharmaceuticals
Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Collegium Pharmaceutical stock logo

Collegium Pharmaceutical NASDAQ:COLL

$32.10 +0.53 (+1.68%)
As of 02:18 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Enliven Therapeutics stock logo

Enliven Therapeutics NASDAQ:ELVN

$21.90 +1.98 (+9.91%)
As of 02:18 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

2seventy bio stock logo

2seventy bio NASDAQ:TSVT

$5.00 0.00 (0.00%)
As of 05/13/2025

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

X4 Pharmaceuticals stock logo

X4 Pharmaceuticals NASDAQ:XFOR

$1.67 +0.00 (+0.06%)
As of 02:17 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.